

7. The pharmaceutical composition of claim 6, wherein the compound of formula I is (*S*)-*N*-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide, the co-crystal former is adipic acid; or
- wherein the compound of formula I is (*S*)-*N*-methyl-8-(1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide, the co-crystal former is adipic acid.
8. The pharmaceutical composition of claim 7, wherein the molar ratio of the compound of formula I to adipic acid is about 2 to 1.
9. A method of making a co-crystal comprising:
- a) grinding, heating, co-subliming, co-melting, or contacting either (*S*)-*N*-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide or (*S*)-*N*-methyl-8-(1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide with a co-crystal former under crystallization conditions so as to form the co-crystal in solid phase, wherein the co-crystal former is adipic acid; or
- b) providing a pre-existing co-crystal as a seed to prepare the co-crystal, wherein the pre-existing co-crystal comprises: (i) either (*S*)-*N*-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide or (*S*)-*N*-methyl-8-(1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide; and (ii) adipic acid; and the co-crystal to be formed comprises: (i) either (*S*)-*N*-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide or (*S*)-*N*-methyl-8-(1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide; and (ii) adipic acid.
10. A co-crystal of any one of claims 1-5, or a pharmaceutical composition of any one of claims 6-8, for use in
- a) potentiating a therapeutic regimen for the treatment of cancer in a patient; or
- b) treating cancer in a patient.
11. The co-crystal of any one of claims 1-5, or a pharmaceutical composition of any one of claims 6-8, for use in treating cancer in a patient according to claim 10, and to be used in combination with an additional anticancer therapy; optionally